PELOSI, NANCY BUYNVDA$500K–$1M·TUBERVILLE, TOMMY BUYMSFT$50K–$100K·CRENSHAW, DAN SELLXOM$15K–$50K·PELOSI, NANCY BUYNVDA$500K–$1M·TUBERVILLE, TOMMY BUYMSFT$50K–$100K·CRENSHAW, DAN SELLXOM$15K–$50K·
← Leaderboard
MRK
Ticker

MRK

Merck & Co. Inc.
Healthcare
Congressional Trades
100
by 23 members
Buys
43
43%
Sells
54
54%
Total Volume
$2.0M
midpoint
Unique Traders
23
members

Party Breakdown

Democrats65 · 65%
Republicans35 · 35%

Party Trading Divergence

Democrat vs. Republican buy / sell pressure by monthMODERATE

Bar length = total trades. Color = net sentiment — green = net buying, red = net selling. Months with no activity hidden.

Democrat ←
Month
→ Republican
Oct '23
01
1
Dec '23
1
Feb '24
01
01
Jun '24
01
Jul '24
Aug '24
3
12
Sep '24
01
2
Oct '24
11
Nov '24
02
16
Jan '25
03
3
Feb '25
11
02
Mar '25
11
31
Apr '25
22
15
May '25
12
5
Jun '25
23
12
Jul '25
32
Aug '25
03
03
Sep '25
Oct '25
01
22
Nov '25
22
Dec '25
Jan '26
01
2
Feb '26
1
Mar '26
Democrats3030Neutral
vs
Republicans1022Net sellers
Net buyingNet selling⚡ Party split

🏛️ Federal Contracts

all →
  • 2026-04-15$23K
    Department of Veterans Affairs
    WELIREG 40 MG
  • 2026-03-27$361.3M
    Department of Health and Human Services
    VACCINES FOR CHILDREN
  • 2026-02-27$21K
    Department of Veterans Affairs
    WINREVAIR 45MG - EMERGENCY PHARMACEUTICAL
  • 2026-02-12$18K
    Department of Justice
    MERCK TRAVEL VACCINES
  • 2026-02-09$21K
    Department of Veterans Affairs
    EMERGENCY PHARMACEUTICAL - WINREVAIR 45MG/VIAL
  • 2026-01-21$21K
    Department of Veterans Affairs
    WINREVAIR 90 MG KIT
  • 2026-01-16$21K
    Department of Veterans Affairs
    EMERGENCY PHARMACEUTICAL - WINREVAIR 45MG
  • 2026-01-13$96K
    Department of Veterans Affairs
    WINREVAIR, SOTATERCEPT-CSRK 60MG/VIAL INJ,LYPHL NDC: 00006-5091-01

💼 Lobbying Filings

all →
  • 2026-04-20$4.2M
    MERCK & CO INC
    S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2027 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues
  • 2026-04-20$70K
    MERCK & CO. INC.
    Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes. Issues related to tariffs.
  • 2026-04-20$50K
    MERCK & CO INC
    Drug pricing proposals. Pharmacy Benefit Manager reform proposals, clinical trial reforms, 340B. Vaccine safety and access issues, FDA reforms and changes, drug supply and shortage issues. Tax policy impacting health care and pharmaceutical industry; implementation of PL 119-21. Drug pricing proposals. Pharmacy Benefit Manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation and ORPHAN CURES Act, Implementation of IRA, and policy changes including the EPIC Act, Medicaid drug rebate program, Issues related to drug pricing in Medicare Parts B and D; Issues related to Most Favored Nation (MFN) drug pricing proposals. General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Pharmacy Benefit Manager (PBM) policy issues. Monitor Section 232 investigations, new trade agreements and tariffs, pharmaceutical IP.
  • 2026-04-20$50K
    MERCK
    Federal budget issues IRA, innovation, drug pricing in federal programs, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars, PAHPA IRA, Medicare and Medicaid payment and coverage issues
  • 2026-04-20$50K
    MERCK & CO. INC.
    340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues. Drug Pricing. S.864: HELP Copays Act.
  • 2026-04-20$50K
    MERCK & CO. INC.
    Issues related to vaccines; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC) Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to the implementation of the Inflation Reduction Act of 2022; Issues related to Senate Finance Dear Colleague process
  • 2026-04-20$40K
    MERCK & CO. INC.
    Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) imp
  • 2026-04-19$80K
    MERCK KGAA DARMSTADT GERMANY
    Issues related to chemical manufacturing. Issues related to domestic and international trade and tariff policies. Issues related to life sciences, laboratory and chemical manufacturing.
  • 2026-04-19$50K
    TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC)
  • 2026-04-18$50K
    MERCK & CO. INC.
    Education around access to vaccines. Public Law 119-21: One Big Beautiful Bill Act.

Congressional Momentum

buy vs. sell pressureACCUMULATING

Score 0–100: above 50 = net buying pressure, below 50 = net selling. Signal based on last 90 days.

Last 30 Days
No trades
Last 90 Days
100
1 buy1 total0 sells
$33K buys · $0 sells
All-Time
40
43 buys99 total56 sells
$799K buys · $1.2M sells
Cumulative Net Position (buy vol − sell vol)
-$410K
2021-03100 trades plotted2026-03

Trade Activity Timeline

Congressional buys & sells by month · last 24 months w/ activity

23/10
23/12
24/02
24/06
24/07
24/08
24/09
24/10
24/11
25/01
25/02
25/03
25/04
25/05
25/06
25/07
25/08
25/09
25/10
25/11
25/12
26/01
26/02
26/03
BuysSellsOtherHigh-volume month

Who Moved First

each row = one member · sorted by earliest disclosed trade
15 buyers ·21 sellers
20222023202420252026RTommy Tuberville3×2021-03-29 · sell · $8K2022-03-30 · buy · $8K2023-10-16 · sell · $8KDJared Moskowitz6×2023-02-24 · buy · $8K2023-12-28 · buy · $8K2024-11-08 · buy · $8K2025-01-15 · sell · $8K2025-01-15 · sell · $8K2025-01-15 · sell · $8KDRo Khanna18×2024-02-13 · buy · $33K2024-07-01 · sell · $33K2024-10-14 · buy · $8K2024-11-15 · sell · $33K2025-01-17 · sell · $33K2025-02-19 · buy · $33K2025-04-04 · buy · $8K2025-04-23 · sell · $33K2025-05-08 · sell · $8K2025-05-09 · sell · $8K2025-05-19 · sell · $8K2025-05-28 · buy · $33K2025-06-20 · buy · $8K2025-06-23 · buy · $33K2025-07-01 · buy · $8K2025-08-04 · buy · $8K2025-09-29 · sell · $8K2026-03-10 · buy · $33KRMichael McCaul10×2024-02-20 · sell · $8K2024-08-02 · buy · $8K2024-11-20 · sell · $75K2024-11-20 · sell · $33K2025-04-02 · buy · $175K2025-05-19 · buy · $75K2025-06-27 · sell · $175K2025-08-22 · sell · $75K2025-10-27 · sell · $33K2026-01-13 · sell · $33KDJosh Gottheimer4×2024-06-21 · sell · $8K2025-01-27 · sell · $33K2026-02-04 · buy · $8K2026-02-04 · buy · $8KRC. Franklin4×2024-08-02 · buy · $8K2024-08-07 · buy · $8K2025-06-16 · sell · $8K2025-06-16 · sell · $8KDRitchie Torres3×2024-09-26 · buy · $8K2025-07-11 · sell · $8K2025-07-11 · sell · $8KDValerie Hoyle3×2024-10-29 · buy · $8K2025-09-23 · sell · $8K2025-09-23 · sell · $8KRByron Donalds3×2025-01-16 · sell · $8K2025-01-16 · sell · $8K2025-01-16 · sell · $8KDJulie Johnson10×2025-01-17 · buy · $8K2025-06-13 · buy · $8K2025-06-13 · buy · $8K2025-06-13 · buy · $8K2025-08-14 · sell · $8K2025-08-14 · sell · $8K2025-11-13 · sell · $8K2025-11-13 · sell · $8K2025-12-18 · sell · $8K2025-12-18 · sell · $8KDGilbert Cisneros14×2025-01-24 · sell · $8K2025-02-26 · buy · $33K2025-02-26 · buy · $33K2025-03-31 · sell · $33K2025-04-29 · buy · $8K2025-04-29 · buy · $8K2025-05-30 · sell · $8K2025-05-30 · sell · $8K2025-08-05 · buy · $8K2025-08-05 · buy · $8K2025-11-18 · buy · $8K2025-11-18 · buy · $8K2025-12-19 · buy · $8K2025-12-19 · buy · $8KRJefferson Shreve2×2025-02-24 · buy · $33K2025-04-17 · sell · $33KRRobert Bresnahan4×2025-02-25 · sell · $33K2025-04-08 · buy · $33K2025-05-15 · sell · $33K2025-05-15 · sell · $33KRBruce Westerman2×2025-03-03 · buy · $8K2025-04-21 · sell · $8KRLisa McClain4×2025-06-24 · buy · $8K2025-06-24 · buy · $8K2025-08-04 · sell · $8K2025-08-04 · sell · $8K
BuySellOtherDot size ∝ trade size · top 15 most-active traders shown

8 less-active traders not shown.

All Disclosed Trades

DateMemberActionAmountFiling Delay
2026-03-10DRo KhannaBUY$15K – $50K28d
2026-02-04DJosh GottheimerBUY$1K – $15K41d
2026-02-04DJosh GottheimerBUY$1K – $15K40d
2026-01-13RMichael McCaulSELL$15K – $50K29d
2025-12-18DJulie JohnsonSELL$1K – $15K29d
2025-12-18DJulie JohnsonSELL$1K – $15K28d
2025-12-19DGilbert CisnerosBUY$1K – $15K25d
2025-12-19DGilbert CisnerosBUY$1K – $15K24d
2025-11-18DGilbert CisnerosBUY$1K – $15K28d
2025-11-18DGilbert CisnerosBUY$1K – $15K27d
2025-11-13DJulie JohnsonSELL$1K – $15K29d
2025-11-13DJulie JohnsonSELL$1K – $15K28d
2025-10-27RMichael McCaulSELL$15K – $50K14d
2025-09-23DValerie HoyleSELL$1K – $15K17d
2025-09-23DValerie HoyleSELL$1K – $15K17d
2025-03-19RSheri BiggsSELL$15K – $50K200d
2025-09-29DRo KhannaSELL$1K – $15K4d
2025-08-05DGilbert CisnerosBUY$1K – $15K41d
2025-08-04RLisa McClainSELL$1K – $15K42d
2025-08-14DJulie JohnsonSELL$1K – $15K29d
2025-08-05DGilbert CisnerosBUY$1K – $15K38d
2025-08-04RLisa McClainSELL$1K – $15K39d
2024-10-29DValerie HoyleBUY$1K – $15K318d
2025-08-22RMichael McCaulSELL$50K – $100K20d
2025-08-14DJulie JohnsonSELL$1K – $15K28d
2025-08-04DRo KhannaBUY$1K – $15K36d
2025-07-11DRitchie TorresSELL$1K – $15K41d
2025-07-11DRitchie TorresSELL$1K – $15K40d
2024-09-26DRitchie TorresBUY$1K – $15K328d
2025-06-24RLisa McClainBUY$1K – $15K51d
2025-06-24RLisa McClainBUY$1K – $15K50d
2025-07-01DRo KhannaBUY$1K – $15K37d
2025-06-16RC. FranklinSELL$1K – $15K29d
2025-06-13DJulie JohnsonBUY$1K – $15K32d
2025-06-16RC. FranklinSELL$1K – $15K28d
2025-06-13DJulie JohnsonBUY$1K – $15K31d
2025-06-23DRo KhannaBUY$15K – $50K16d
2025-06-20DRo KhannaBUY$1K – $15K19d
2025-06-13DJulie JohnsonBUY$1K – $15K26d
2025-06-27RMichael McCaulSELL$100K – $250K10d
2024-08-07RC. FranklinBUY$1K – $15K330d
2025-05-28DRo KhannaBUY$15K – $50K13d
2025-05-19DRo KhannaSELL$1K – $15K22d
2025-05-09DRo KhannaSELL$1K – $15K32d
2025-05-08DRo KhannaSELL$1K – $15K33d
2025-05-30DGilbert CisnerosSELL$1K – $15K10d
2025-05-19RMichael McCaulBUY$50K – $100K21d
2025-05-30DGilbert CisnerosSELL$1K – $15K7d
2025-05-15RRobert BresnahanSELL$15K – $50K18d
2025-05-15RRobert BresnahanSELL$15K – $50K16d
2025-04-23DRo KhannaSELL$15K – $50K19d
2025-04-21RBruce WestermanSELL$1K – $15K21d
2025-04-04DRo KhannaBUY$1K – $15K38d
2025-04-02RMichael McCaulBUY$100K – $250K40d
2025-04-17RJefferson ShreveSELL$15K – $50K21d
2025-04-08RRobert BresnahanBUY$15K – $50K30d
2025-04-29DGilbert CisnerosBUY$1K – $15K8d
2025-04-29DGilbert CisnerosBUY$1K – $15K7d
2025-03-03RBruce WestermanBUY$1K – $15K44d
2025-03-20DKelly MorrisonSELL$1K – $15K22d
2025-03-31DGilbert CisnerosSELL$15K – $50K7d
2025-02-25RRobert BresnahanSELL$15K – $50K30d
2025-02-24RJefferson ShreveBUY$15K – $50K13d
2025-02-26DGilbert CisnerosBUY$15K – $50K8d
2025-02-19DRo KhannaBUY$15K – $50K15d
2025-02-26DGilbert CisnerosBUY$15K – $50K6d
2025-01-17DJulie JohnsonBUY$1K – $15K26d
2025-01-24DGilbert CisnerosSELL$1K – $15K18d
2025-01-27DJosh GottheimerSELL$15K – $50K14d
2025-01-16RByron DonaldsSELL$1K – $15K25d
2025-01-15DJared MoskowitzSELL$1K – $15K26d
2025-01-17DRo KhannaSELL$15K – $50K20d
2025-01-15DJared MoskowitzSELL$1K – $15K16d
2025-01-15DJared MoskowitzSELL$1K – $15K16d
2025-01-16RByron DonaldsSELL$1K – $15K14d
2025-01-16RByron DonaldsSELL$1K – $15K14d
2024-11-20RMichael McCaulSELL$50K – $100K26d
2024-11-20RMichael McCaulSELL$15K – $50K26d
2024-11-08DJared MoskowitzBUY$1K – $15K31d
2024-11-15DRo KhannaSELL$15K – $50K20d
2024-10-14DRo KhannaBUY$1K – $15K25d
2024-09-24DJonathan JacksonSELL$15K – $50K17d
2024-09-24DJonathan JacksonSELL$15K – $50K7d
2024-08-02RMichael McCaulBUY$1K – $15K45d
2024-09-04RJohn JamesSELL$1K – $15K2d
2024-08-02RC. FranklinBUY$1K – $15K18d
2024-07-01DRo KhannaSELL$15K – $50K37d
2024-06-21DJosh GottheimerSELL$1K – $15K18d
2024-02-20RMichael McCaulSELL$1K – $15K24d
2024-02-13DRo KhannaBUY$15K – $50K22d
2023-12-28DJared MoskowitzBUY$1K – $15K3d
2023-10-16RTommy TubervilleSELL$1K – $15K32d
2023-09-21RPete RickettsSELL$50K – $100K29d
2022-03-30RTommy TubervilleBUY$1K – $15K516d
2021-06-02DJohn HickenlooperEXCHANGE$1K – $15K817d
2021-03-29RTommy TubervilleSELL$1K – $15K882d
2023-08-02DLois FrankelPARTIAL_SELL$1K – $15K23d
2023-06-28DLois FrankelPARTIAL_SELL$1K – $15K23d
2022-07-07DRick LarsenBUY$1K – $15K315d
2023-02-24DJared MoskowitzBUY$1K – $15K4d